Warning letter
Aurobindo Pharma Limited: warning letter of Jun 20, 2019
FDA warning letter 577033 · Center for Drug Evaluation and Research
Key facts
| Reference number | 577033 |
|---|---|
| Company | Aurobindo Pharma Limited |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Jun 20, 2019 |
| Posted date | Jul 2, 2019 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 314.97(a), 314.420 |
| Inspection city | Srikakulam |
| Inspection start date | Feb 4, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: